

Health Care Applications of Different Biosurfactants: Review

Jayeeta Sil¹, Parag Dandapat², Subhasish Das³

^{1,2}Department of microbiology, Midnapore College (Autonomous), Paschim Midnapore, PIN- 721101

³Triphase Pharmaceuticals Pvt. Ltd., Mysore – 570016, India

Abstract: *Biosurfactants are amphiphilic compounds produced by certain microorganisms. Bio surfactant molecules arrange themselves in water-oil interface and reduce surface tension. Biosurfactants have some advantages over chemical surfactants in market with respect to biodegradability, low toxicity, better surface and interfacial activity. There are different application of biosurfactants in health care purposes both oral and dermal. Among this some of the important field of application are medicine and cosmetics.*

Keywords: Biosurfactants, microorganisms, applications in pharmacology, cosmetics and personal care.

1. Introduction

Surfactants are generally active ingredients which have the ability to form concentrate at the air- water and oil-water interface. It can separate oily substances from a media by reducing their interfacial tension at water- oil interfaces and form bubbles by reducing air-water interfacial tension. This mainly happens due to increase in aqueous solubility of the Non Aqueous Phase Liquids (NAPLS) (H Yin *et al.* 2009). Surfactants are amphiphilic moieties, both lipophilic and hydrophilic parts. It is widely used in different fields like industrial, agricultural, food, cosmetic, pharmaceutical etc. These compounds are chemically synthesized and create environmental and toxically problems (Schramm *et al.* 2003, Makkar and Rockne, 2003). In the past few decades' surface active molecules having microbial origin has gain interest in this fields. These surface active metabolites are called biosurfactants (Desai and Banat 1997). These are amphiphilic compounds produced on microbial cell surfaces or extracellular both hydrophobic and hydrophilic. These can accumulate between fluid phases and reduce surface and interfacial tension respectively (CD Cunha *et al.* 2004). Biosurfactants constitute a diverse group of surface active molecules and variety of chemical structures like glycolipids, lipopeptides, fatty acids, phospholipids etc. (Desai and Banat, 1997). Biosurfactants has potential application in industrial process as it act as surface active agents in emulsion (Amaral *et al.*, 2009, Huang *et al.*, 2010, Sil *et al.*, 2013). But biosurfactants also found in several health care applications. It possesses several properties in biomedical and therapeutic fields. It has antibacterial, antifungal and antiviral properties (Joshi *et al.*, 2008). Due to its biocompatibility and digestibility biosurfactants also have application in cosmetics and functional food additives (Kosaric 2001). Surface active molecules are mainly two types one that reduce surface tension at the air-water interface known as biosurfactants. Secondly, that reduce the interfacial tension between immiscible liquids or at the solid-liquid interface known as bioemulsifiers (Konishi *et al.* 2007, Langer *et al.* 2006, Freitas *et al.*, 2009). Biosurfactants can reduce both surface tension and exhibits emulsifying capacity (Langer *et al.* 2006, Freitas *et al.*, 2009). As per studies of Desai and Banat (1997) and Gautam and Taigi

(2006) depending on the hydrophilic part, biosurfactants are classified on their composition five types

- 1) Glycolipids: carbohydrates with long chain aliphatic acids. Best known are rhamnolipids, sophorolipids, trehalolipids, mannosylerythritol and cellobiose lipids, liamocins and exophilins, alkyl and acyl glycosides, polymeric exopolysaccharides (Morita *et al.*, 2006, Sullivan, 1998; Kitomoto *et al.*, 1993).
- 2) Lipopeptides and lipoproteins: includes decapeptides (gramicidins) and lipopeptide antibiotics (polymyxins) are important.
- 3) Fatty acids, phospholipids and neutral lipids: Several bacteria and yeasts produce growth on n-alkanes.
- 4) Polymeric biosurfactants: Emulsan (also under glycolipid class), liposan, mannoprotein and other polysaccharide-protein complexes (also under lipoprotein class).
- 5) Particulate biosurfactants: form micro emulsion and plays important role in in alkane uptake by microbial cells (Monteiro *et al.*, 2007; Mukherjee *et al.*, 2006; Ortiz *et al.*, 2006).

Biosurfactants have huge structural diversity. Majority includes low molecular weight glycolipids (GLs), lipopeptides (LPS), flavolipids (FLs) and phospholipids. While high molecular weight polymers like lipoproteins, lipopolysaccharide protein complexes, polysaccharides protein fatty acid complexes etc. (Rodrigues *et al.*, 2006b; Ruiz-Garc *et al.*, 2005; Singh *et al.*, 2007).

2. Application of biosurfactants in health care purposes

There worldwide production of surfactants and expected increase growth rates of 3-4% per year globally (Rahman *et al.* 2008). But chemically synthesized surfactants are mainly petroleum based and non biodegradable and toxic to living beings. So to protect the ecosystem scientists are interest in surfactants formed from microbial origin i.e. biosurfactants as a alternatives of the chemical ones (Benincasa 2007). These biosurfactants have several applications in agriculture, medicine, petroleum and industries. Here we will discuss on the health care benefits of biosurfactants and their application for different purposes.

Biosurfactants have different bioactivities. Some are like it inhibit bacterial growth (Flagas and Makris, 2009), toxic effects, tumor growth inhibition, antibiotics, cell lysis (Dehghan-Noudeh et al., 2005), food digestion (Nitschke and Costa 2007), fungicidal properties (Joshi et al., 2008) or enzyme stimulation etc. These bio molecules have different uses in health benefits: pharmaceuticals, testing quality of condoms, cosmetics, beer and beverages (Mukherjee et al., 2006) and food processing (Arauz et al., 2009).

3. Antimicrobial activity

Biosurfactants have manifold activities ranging from antibacterial, antiviral, antimycobacterial to antimycoplasmal activities (Vollenbroich et al., 1997a; Rodrigues et al., 2006b; Rahman et al. 2003). Some antimicrobial lipopeptide like iturin, surfactin, lichenysin etc. are active against some human pathogens *Candida* sp. Marine *B. circulans* produces lipopeptide biosurfactant had a potent antimicrobial activity against Gram positive and Gram negative pathogens (Gharaei-Fathabad 2011, Das et al. 2008a). Surfactin a best known lipopeptides produce by *Bacillus subtilis* has antimicrobial activity. Antimicrobial lipopeptides produced by some *Bacillus* species inhibit the growth of pathogenic microorganisms in gastrointestinal tract (Hong et al., 2005). *Bacillus subtilis* fmbj produces lipopeptides mainly composed of surfactin and fenygin antimicrobial substances. It has the ability to inactivate the endospores of *B. cereus* (Huang et al., 2007). Rhamnolipid biosurfactant produced from soyabean oil waste has antimicrobial activity against several bacteria and fungi (Nitschke et al. 2009b). Antimicrobial activities of glycolipids are effective against *Staphylococcus* sp. mainly on methicillin resistant *Staphylococcus aureus* (MRSA) (Das et al., 2008a). *Candida antarctica* produces mannosylerythritol lipids (MEL-A and MEL-B) which has antimicrobial action against Gram-positive bacteria (Kitamoto et al., 1993).

4. Anti-Adhesive Activity

According to Rodrigues et al. (2006) biosurfactants inhibits the adhesion of pathogenic organisms to solid surfaces or to the infection site. Again absorption of biosurfactants to the substratum alters the hydrophobicity of the surface and causes microbial adhesion and desorption processes (Desai and Banat, 1997; Bai et al., 1997). Biosurfactants reduces the microbial population on prostheses and decreases the airflow resistance that occurs on voice prostheses after biofilm formation (Rodrigues et al., 2004). Biosurfactant can alter the physical and chemical condition of the environment where biofilm is forming and has direct action against pathogens (Mireles et al., 2001, Merck et al., 2005). It has been found that two lipopeptide biosurfactants produced by *B. subtilis* V9T14 and *B. licheniformis* VI9T2I1 has interesting anti-adhesive activity that inhibit the biofilm formation by two pathogenic strains mainly *S. aureus* ATCC 29213 and *Escherichia coli* CFT073 (Rivardo et al., 2009). Serotypes of group II capsular polysaccharides produced by uropathogenic *E. coli* (UPFC strain CFT073) behave like surface active polymers and has good anti-adhesive properties. It inhibits mature bio film development of broad range Gram positive bacteria and Gram negative bacteria

(Valle et al., 2006). It has been found that biosurfactant of *Streptococcus mitis* inhibits addition of *Streptococcus sorinus* HG 1025 and *S. mutans* ATCC 25175 to bare enamel (Van Hoogmoed et al., 2004). Also, *S. mitis* inhibits the adhesion of *S. sorinus* HG 1025 to salivary pellicles.

5. Immunological Adjuvant

Certain bacterial lipopeptides are potent non-toxic, non pyrogenic immunological adjuvant when mixed with conventional antigens. Low molecular weight antigen iturin AL, herbicolin A and Microcystin coupled with poly-L-lysine enhances humoral immune response in rabbits and chickens (Rodrigues et al., 2006b). Emulsan has been approved for use as adjuvant because it has immunomodulatory potential in human body.

6. Antiviral Activity

Surfactin and its analogues show antiviral activity (Naurse et al., 1990). Vollenbroich et al. (1997) suggested that antiviral activity of surfactin on enveloped viruses are more prominent than on non-enveloped viruses mainly due to physico-chemical interactions between virus envelope and the surfactant. Biosurfactants have been known to inhibit growth of human immunodeficiency virus in leucocytes (Desai and Banat 1997; Krishnaswamy et al., 2008). According to Krishnaswamy et al. (2008) sophorolipids from *C. bombicola* and its structural analogues such as the sophorolipid diacetate ethyl ester is potent anti-HIV, cytotoxic activities and virucidal agent.

Cell free virus of porcine parvovirus, pseudo rabies virus, Newcastle disease virus and bursal disease virus are inactivated by antimicrobial lipopeptides produced by *B. subtilis* fmbj. This lipopeptide also has the ability to inhibit the replication and infectivity of the Newcastle disease virus and bursal disease virus but not effective on pseudo rabies virus and porcine parvovirus (Huang et al., 2006). Rhamnolipids and their complexes with alginate produced by *Pseudomonas* sp. have antiviral activity against Herpes simplex viruses type 1 and 2 (Remichkova et al., 2008).

7. Anti-Fungal Activity

Biosurfactants have anti-fungal activities against human pathogens. Yeast like fungus *P. flocculosa* produces a glycolipid known as flocculosin shows *in vitro* anti-fungal activity against pathogenic yeasts and also effective against human mycoses (Mimee et al., 2005). This product can inhibit pathogenic strains in acidic condition and has synergistic activity against amphotericin B. There are different glycolipids like cellobiose lipids (Teichmann et al., 2007; Kulakovskaya et al., 2009, Kulakovskaya et al. 2010) shows antifungal activity against phytopathogenic fungi. Other biosurfactants are Rhamnolipids, cyclic lipopeptides, surfactin, iturin and fenygin also has anti-fungal activities (Debode et al., 2007; Varnier et al., 2009, Tran et al., 2007, 2008, Velmurugan et al., 2009; Snook et al., 2009; Mohammadipour et al., 2009; Grover et al., 2010).

Anti-cancer activity, immunomodulatory action, Anti-tumor and

Some biosurfactants are involved in cancer cell proliferation and apoptosis (Gudina *et al.*, 2013). Some glycolipids have been found to induce cell differentiation in the human promyelocytic leukemia cell line and act as novel reagents for cancer cells treatment (Krishnaswamy *et al.*, 2008). These glycolipids arrest the cell growth and induce apoptosis of mouse malignant melanoma B16 cells. It was found that with increase in concentration of the MELs, B16 cells showed tendency of accumulation in the sub - G0/ G1 phase indicating cell death (Zhao *et al.*, 2000) as shown in figure 2. Apoptosis induced by MELs activate protein kinase C (PKC) which leads to a multiplication of cellular responses. MELs also induce the differentiation of human promyelocytic leukemia HL60 cells towards granulocytes. Hence MEL biosurfactants trigger both apoptotic and differentiation mechanisms (Gudina *et al.*, 2013; Zhao *et al.*, 2000; Isoda *et al.*, 1997). Sophorolipids also found to trigger

cell differentiation and to inhibit PKC activity in the HL60 human leukemia cell line (Isoda *et al.*, 1995). Sophorolipid produced by *Wickerhamiella domercqiae* induces apoptosis in H7402 human liver cancer cells by blocking the cell cycle at G1 phase shown in figure 2, activating caspase-3 and increasing Ca^{2+} concentration in the cytoplasm (Chen *et al.*, 2006). According to Kim *et al.* (2007) surfactin blocks cell proliferation by inducing proapoptotic activity and arresting the growth in G2/M phase of the cell cycle as in figure 1. It has been found that surfactin is a best biosurfactant that induces apoptosis in human breast cancer MCF-7 cells through JNK-mediated caspase pathway (Cao *et al.*, 2010). Surfactin also induces apoptosis in HepG2 cells through ROS-endoplasmic reticulum stress (ERS)- Ca^{2+} - extracellular signal-regulated protein kinase pathways (Wang *et al.*, 2013). There are other bacteria sp. Like *Bacillus*, *Pseudomonas*, *Serratia* produces different lipopeptides which exhibit antitumoral activities against various human cancer cells (El-Sersy *et al.*, 2012).




Figure 1

Cord factor or Trehalose-6, 60-dimycolate (TDM) exhibits anti-tumor and immunomodulatory activities. But Mycobacterial TDM has limited use due to high toxicity of the molecule and potential pathogenicity of the producer strains. TDM is also produced by *Rhodococcus* sp. 4306 but low toxicity (Francetti *et al.*, 2010). Surfactin, a biosurfactant has powerful anti-inflammatory, antibiotics and anti-tumor function (Seydlová and Svobodová 2008). Surfactin inhibits the immunostimulatory function of macrophages by blocking NK- κ B, MAPK, AKt pathway (Park and Kim 2009). Surfactin also plays immunopharmacological role in autoimmune disease and transplantation. Surfactin also has potent

immunosuppressive capability which shows therapeutic application in autoimmune disease and transplantation. It has been found that *Bacillus subtilis* PB6 which produce surfactin. This surfactin inhibits enzymes phospholipase A2 that release fatty acids from second carbon group of glycerol. This involves in pathophysiology of inflammatory bowel disease (Selvam *et al.*, 2009). Kinetic study in interaction of carbohydrate ligand system composed of self-assembled monolayers mannosylerythritol lipid-A(MEL-A) produced by *P. antarctica* easy to handle. It serve as low cost ligand system for IgM and IgG and also lectins (Konishi *et al.*, 2007a). A fungus *Exophiala dermatitidis* SK80 produces a biosurfactant monoolein which can inhibit the

proliferation of cervical cancer (HeLa) and leukemia (U937) cell lines depending on doses (Chiewpattanakul et al., 2010).

There are differences in the cell membrane lipid profile of normal and cancerous tissues. It is known that lipids are surface active in nature, thus with the change in lipid profiles surface activity profiles also changes in the cells. Thus when biosurfactants interact with lipid profiles which is also surface active in nature it lead to cell membrane modifications and ultimately to cell death. Lipid composition mainly determines the structure, function, integrity of biological membranes, phosphatidylcholine (PC) and sphingomyelin (SM) which plays important role in stabilizing the bilayer structure of the cells. It has been reported that changes in PC and SM levels might affect the permeability of the cancer cell membranes. Thus research has designed a new therapeutic strategies that use of biosurfactants might alter lipid content (specially PC and SM) which in turn fluidize rigid cancerous tissues and also modulate interfacial properties (Preetha et al., 2005).

8. Gene Delivery

Introducing exogenous nucleotides into mammalian cells for basic sciences and clinical applications such as gene therapy. Various methods for gene transfection, lipofection (Zhang et al., 2010; Fujita et al., 2009; Liu et al., 2010) using cationic liposomes to deliver foreign gene to the target cells without side-effects. It has been found that liposomes based on biosurfactants show increasing efficiency of gene transfection than commercially available cationic liposomes (Kitamoto et al., 2002). New techniques and methodologies are developed for the liposome-based gene transfection by introducing biosurfactants (Ueno et al., 2007). Cellular association and efficiency of gene transfection mediated by cationic liposomes increased by MEL-A (Igarashi et al., 2006). It was observed by Ueno et al., 2007, that among MEL-A, MEL-B and MEL-C- containing liposomes only MEL-A has high activity in DNA capsulation and membrane fusion with anionic liposomes. These are important properties of for gene transfection. Maitani et al., 2006 was successful in producing a liposome vector containing beta-sitosterol beta- D- glucoside biosurfactant complexed DNA used for herpes simplex virus thymidine kinase gene therapy. 2009 Nakanishi et al., was able to produce nano-vectors containing a biosurfactant that increase the efficacy for gene transfection *in vivo* and *in vitro*. Surfactin - mediated gold nanoparticles has opened a new and fascinating application in the field of drug , gene delivery, and targeted therapy etc.(Reddy et al., 2009).

9. Recovery of intracellular products

According to Singh et al., 2007 biosurfactants used for lysis of cells after fermentation as part of the protocol for recovery of intracellular products. Overall releases of intracellular proteins from microbial cells are done by aggressive mechanical cell disintegration methods. For selective permeabilization reagents are used which render the cell envelope more porous which is beneficial for selective release of target proteins and to obtain an extracted product with a high specific activity or for further protein

purification. As demonstrated by Desai and Banat, 1997, biosurfactants can be used as reagents for membrane permeabilization. It is important to note that biosurfactant has no negative impact on the stability or activity of the product as it binds to the proteins and other bioactive molecules (Desai and Banat, 1997; Singh et al., 2007).

Other uses of biosurfactants in medicine are used for stimulating stem fibroblast metabolism etc (M. Krishnaswamy et al., 2008).

10. Application and benefits of biosurfactants in cosmetics and personal care:

A ideal surfactant to be used in cosmetics must have properties like detergency, wetting, emulsifying, solubilising, dispersing and foaming effects (Rieger et al., 1997). Biosurfactants which are produced by microorganisms, have drawn wide attention regarding their biodegradability, low toxicity, ecological acceptability and availability from renewable sources (Makkar and Cameotra, 1999). Most widely used biosurfactants are glycolipids in nature due to their physiochemical properties, biological activities, biocompatibility and biodegradability (Desai and Banat, 1997). Potential glycolipid biosurfactants used as multifunctional ingredients in the formulation of cosmetics are sophorolipids, rhamnolipids and mannosylerythritol lipids.

Sophorolipids- It is originally obtained from the yeast *Candida* species. Main strains were *C. bomicola* ATCC 22214 (Spencer et al., 1970; Ashby et al., 2006) and *C. apicola* IMET 42747 (Hommel et al., 1994) produces sophorolipids as a mixture of 2-O-β-D-gluco-pyranose derivatives acetylated at the 6' and/or 6" positions. Beside *Candida* sp. *Wickerhamiella domericquae* (Chen et al., 2006; Chen et al., 2006) as well as *Cryptococcus curvatus* (Daniel et al., 1998) also synthesize sophorolipids. It was found that mono- and di-acetylated lactones showed strongest inhibitory effects and also could find numerous applications than the acidic forms of sophorolipid (Lang et al., 1989).

Application- It has shown several cosmetic applications like good skin compatibility and have excellent moisturizing properties (Yamane 1987; Brown 1991). Due to its emulsifying functions act as potent bactericidal agents and used in the treatment of acne, dandruff and body odours (Mager et al., 1987). Sophrolipids act as desquamating and depigmenting agents (Hillion et al., 1998; Borzeix et al., 2003; Maingault et al., 1999). So several patients are related to sophorolipids in cosmetics (Kawano et al., 1981). Commercially sophorolipids are produced by the Kao Co. Ltd. as humectants and present make-up as "Sofina" and "Soliance" which are sed for skin application. Beside these products , sophorolipids are also used in pencil-shaped lip rouge, lip cream, eye shadow and compressed powdered cosmetics and aqueous solutions (US Patent 4 305 931, US Patent 4 305 929).

Rhamnolipids- Rhamnolipids generally produced by *Pseudomonas* sp., and *P. aeruginosa* produces leading commercial biosurfactant which is suitable form in case of

Besides these potential surfactants it is found that highly biosurfactants derived from yeasts act as moisturizing activity which is equivalent to that of natural ceramides at one tenth of the cost of current products. Dai Kitamoto, group Leader of the Biochemical Materials Group of Research Institute for innovation in Sustainable Chemistry, of the National institute of AIST (Advanced Industrial Science and Technology) collaborated with Toyobo Co. Ltd and has succeeded in developing a highly functional biosurfactants from yeast cells and vegetable oils. These developed biosurfactants present super skin moisturizing characteristics same as natural ceramides. These biosurfactants are only sugar and fatty acids and eco-friendly and easily form a variety of crystals in aqueous solutions

(AIST press release september 7, 2006). In figure 3 we have tried to compare the mechanisms of normal skin, dry skin and skin applied with biosurfactants. It has been found that when the ceramide level remains normal in the skin the water level in the skin also remain normal shown in figure 3A. Skin is found normally moisturised and smooth. But when the ceramide level decreases the normal water content also decreases slowly in the skin. This makes the skin dry and rough in nature and also aging & wrinkling problems comes with it shown in figure 3B. In case of using artificial ceramide if we use biosurfactant containing natural ceramide it will moisturise the skin and retain water level as in figure 3C.




Figure 3
References

11. Conclusion

Chemically synthesized surface active compounds are though easily available in the market and widely used in different industry. But biosurfactants has advantages of biodegradability and production on renewable resource substrates which replaces the chemical surfactants. There are different health care applications and benefits of biosurfactants that replaces chemical surfactants. But there is also need to give for attention on the improvement of the physiology, genetics and biochemistry of biosurfactant producing strains (Youssef *et al.*, 2004, 2007; Zang and Miller, 1992; Zouboulis *et al.*, 2003). So that we can get more yield and available in market in reduce production costs.

12. Acknowledgements

We are thankful to our honourable Principal Dr.G.C Bera ,Midnapore College(Autonomous), West Bengal, PIN-721101.

- [1] Yin H, Qiang Y, Jia Y, Ye J, Peng H, et al. (2009) Characteristics of biosurfactant produced by *Pseudomonas aeruginosa* S6 isolated from oil – containing wastewater. *Process Biochem* 44: 302-308.
- [2] Makkar, R.S. and K.J. Rockne, 2003. Comparison of synthetic surfactants and biosurfactants in enhancing biodegradation of polycyclic aromatic hydrocarbons. *Environ. Toxicol. Chem.*, 22: 2280-2292.
- [3] Schramm, L.L., E.N. Stasiuk and D.G. Marangoni, 2003. Surfactants and their applications. *Ann.Rep.Program Chem. Sec.*, 99:3-48.
- [4] Desai J.D. and I.M. Banat, 1997. Microbial production of surfactants and their commercial potential. *Microbiol.Mol.Biol.Rev.*, 61: 47-64.
- [5] Cunha CD, Do Rosario M, Rosado AS, Leite SGF (2004) *Serratia sp* SVGG 16:
- [6] A promising bio-surfactant producer isolated from tropical soil during growth with ethanol-blended gasoline. *Process Biochem* 39: 2277-2282.
- [7] Joshi, S.C. Bharucha, A.J Desai, 2008. Production of biosurfactant and antifungal compound by fermented food isolate *Bacillus subtilis* 20B. *Bioresour.Technol.*, 99: 4603-4608.

- [8] Kosaric N (2001) Biosurfactants and their Applications for Soil Bioremediation. *Food Technol Biotechnol* 39: 295-304.
- [9] Freitas, F., V.D. Alves, M. Carvalheira, N. Costa, R. Oliveira and M.A.M.Reis, 2009. Emulsifying behaviour and rheological properties of extracellular polysaccharide produced by *Pseudomonas oleovorans* grown on glycerol by product. *Carbo Polymer*, 78: 549-556.
- [10] Langer, O., O. Palme, V. Wray, H. Tokuda and S.Lang , 2006. Production and modification of bioactive biosurfactants . *Process Biochem.*, 41: 2138-2145.
- [11] Rodrigues, L., I.M. Banat, J. Teixeira and R.Oliveira, 2006b. Biosurfactants: Potential applications in medicine. *J. Antimicrobial Chemotherapy*, 57: 609-618.
- [12] Ruiz-Garc, C., E. Quesad, E.Martnez-Checa, I.Liamas,M.C. Urdaci and V.Be Jar, 2005. *Bacillus axarquiensis* sp. nov. and *Bacillus malacitensis* sp. nov., isolated from river- mouth sediments in Southern Spain. *Int. J. Syst. Evol.Microbiol.*, 55: 1279-1285.
- [13] Singh, A., J.D. Hamme and O.P. Ward, 2007. Surfactants in microbiology and biotechnology. part 2. Application aspects. *Biotechnol. Adv.*, 25: 99-121.
- [14] Rahman PKSM,GakpeE(2008) Production, Characterization and application of Biosurfactants-Review. *Biotechnology* 7: 360-370.
- [15] Benincasa M (2007) Rhamnolipid produced from agro industrial wastes enhances hydrocarbon biodegradation in contaminated soil. *Curr Microbiol* 54: 445-449.
- [16] Flagas, M.E and Makris, 2009. Probiotic bacteria and biosurfactants for nosocomial infection control: A hypothesis. *J. Hospital Infection*, 71: 301- 306.
- [17] Dehghan-Noudeh, G.M. Housainkht and B.S.F. Bazzaz, 2005. Isolation, characterization and investigation of surface and hemolytic activities of a lipopeptide biosurfactant produced by *Bacillus subtilis* ATCC 6633. *J. Microbiol.*, 43: 272-276.
- [18] Nitschke, M. and S.G. Costa, 2007. Biosurfactants in food industry. *Trends Food Sci. Technol.*, 18: 252-259.
- [19] Mukherjee S. , Das P., Sen R., (2006) Towards commercial production of microbial surfactants. *Trends Biotechnol* 24:509-515.
- [20] Arauz, L.J., A. F. Jozala, P.G. Mazzola and T.C.V. Penna, 2009. Nisin biotechnological production and application: A review. *Trends Food Sci. Technol.*, 20: 146-154.
- [21] Vollenbroich, D., Özel, M., Vater, J., Kamp, R.M., Pauli, G., 1997b. Mechanism of inactivation of enveloped viruses by the biosurfactant, surfactin from *Bacillus subtilis*. *Biologicals* 25, 289–297.
- [22] Bai, G., Brusseau, M.L., Miller, R.M., 1997. Biosurfactant-enhanced removal of residual hydrocarbon from soil. *J. Contam. Hydrol.* 25, 157–170 .
- [23] Rodrigues, L., H.C.V. Mei, J. Teixeira and R.Oliveira, 2004. influence of biosurfactants from probiotic bacteria on formation of biofilms on voice protheses. *Applied Environ.Microbiol.*, 70: 4408-4410.
- [24] Krishnaswamy M, Subbuchettiar G, Ravi T.K., Panchaksharam S (2008) Biosurfactants properties, commercial production and application. *Current Science* 94: 736-747.
- [25] Kitamoto, D., Isoda H. and T.N. Hara, 2002. Functions and potential applications of glycolipid biosurfactants- from energy -saving materials to gene delivery carriers. *J.Bio. Sci. Bio. Eng.*, 94: 187-201.
- [26] Liu, J., A. Zou and B. Mu, 2010. Surfactin effect on the physiochemical property of PC liposome. *Colloids Surfaces A: Physicochem. Eng. Aspects*, 10.1016/j.colsurfa. 2010.03.021.
- [27] Ueno., Y., N. Hirashima, Y. Inoh, T. Furuno and M. Nakanishi, 2007. Characterization of biosurfactant-containing liposomes and their efficiency for gene transfection. *Biol. Pharm. Bull.*, 30: 169-172.
- [28] Zhang, Y., H. Li, J.Sun, J. Gao, W. Liu, B. LI, Y. Guo and J. Chen, 2010. Dc-cho/Dope cationic liposomes: A comparative study of the influence factors on plasmid pDNA and Si RNA gene delivery. *Int. J, Pharm.*, 390: 198-207.
- [29] Rieger, M.N. Surfactant chemistry and classification. In: *Surfactants in Cosmetics*, 2nd edn (Rieger, M.N and Rhein, L.D., eds), p.2. Merceel Dekker, New York(1997).
- [30] Makkar,R.S. and Cameotra, S.S. Biosurfactant production by microorganisms on unconventional carbon sources- a review. *J.Surfact.Deterg.*2, 237-241(1999).
- [31] Spencer, J.F. T., Gorin, P.A.J. and Tulloch, A.P. *Torulopsis bombicola* sp. *Antonie van Leeuwenhoek* 36, 129-133(1970).
- [32] Ashby, R.D., Solaiman, D.K.Y. and Fogli, T.a. The use of fatty acid esters to enhance free acid sophorolipid synthesis, *Biotechnol, lett.* 28, 253-260 (2006).
- [33] Hommel, R.K., Weber, L., Weiss, A. et al. Production of sophorose lipid by *Candida (Torulopsis) apicola* grown on glucose. *J. Biotechnol.* 33. 147-155 (1994).
- [34] Chen, J., Song,X.,Zhang, H. *et al.* Production, structure elucidation and anticancer properties of sophorolipids from *Wickerhamiella domericquae*. *Enzyme Microb. Technol.* 39. 501-506 (2006).
- [35] Chen, J., Song, X., Zhang, H. et al. Sophorolipid produced from the new yeast strain *Wickerhamiella domericquae* induces apoptosis in H7402 human liver cancer cells. *Appl. Microbiol. Biotechnol.* 72,52-59(2006).
- [36] Daniel, H.J., Reuss, M. and Syldatk, C. Production of sophorolipids in high concentration from deproteinized whey and rapeseed oil in a two stage fed batch process using *Candida bomicola* ATCC 22214 and *Cryptococcus curvatus* ATCC 20509. *Biotechnol. Lett.* 20, 1153-1156(1998).
- [37] Yamane, T. Enzyme technology for the lipid industry. A engineering overview. *J.Am. Oil Chem. Soc.* 64, 1657-1662(1987).
- [38] Brown M.J. Biosurfactants for cosmetic applications. *Int.J.Cosmet.Sci.* 13,61-64(1991).
- [39] Mager, H., Rothlisberger, R. and Wagner, F. Use of sophorose- lipid lactone for the treatment of dandruffs and body odor(European Patent 0 209 783). Institut Francais du Petrole, Malmaison (1987).
- [40] Hillion, G., Marchal, R., Stoltz, C, and Boreix, C.F. Use of a sophorolipid to provide free radical formation inhibiting activity or elastase inhibiting activity (US Patent 5 756 471). Institut Francais du Petrole, Malmaison (1998).

- [41] Borzeix, C.F. Use sophorolipids comprising diacetyl lactones as agent for stimulating skin fibroblast metabolism (US Patent 6 596 265). Institut Francais du Petrole, Malmaison(2003).
- [42] Maingault, M. Utilization of sophorolipids as therapeutically active substances or cosmetic products in particular for the treatment of the skin (US Patent 5 981 497), Institut Francais Du petrole, Malmaison (1999).
- [43] Kawano, J., Suzuki, T., Inoue, S. and Hayashi, S. Powered compressed cosmetic material (US Patent 4 305 931). Kao Soap Co., Ltd., Tokyo (1981).
- [44] Kawano, J., Suzuki, T., Inoue, S. and Hayashi, S. Stick-shaped cosmetic material (US Patent 4 305 929). Kao Soap Co., Ltd., Tokyo (1981).
- [45] Van Haesendonck, I.P.H., & Vanzeveren, E.C.A. (2004). Rhamnolipids in bakery products W.O. 2004/040984, International application patent (PCT).
- [46] Busscher, H.J., van Hoogmoed. C. G>, Geertsema-Doornbusch, G.I., van der Kuij-Booij, M., & van der Mei, H.C. (1997). *Streptococcus thermophilus* and its biosurfactants inhibit adhesion by *Candida* spp. on silicone rubber. Applied and Environmental Microbiology, 63, 3810e3817.
- [47] Gan, B. S., Kim, J., Reid, G., Cadieux, P., & Howard, J.C. (2002). *Lactobacillus fermentum* RC-14 inhibits *Staphylococcus aureus* infection of surgical implants in rats. Journal of Infectious Diseases. 185(9), 1369e1372.
- [48] Youssef, N.H., K.E. Duncan, D.D. Nagle, K.H. Savage, R.M. Knapp and M.J. Mcinerney, 2004. Comparison of methods to detect biosurfactant production by diverse microorganisms, J. Microbiol. Methods, 56: 339-347.
- [49] Youssef, N., D.R. Simpson, K.E. Duncan, M.G. Melnerney, M. Folmsbee, M. Fincher and R.M. Knapp, 2007. In situ biosurfactant production by bacillus strains injected into a limestone petroleum reservoir. Applied Environ.Microbiol, 73: 1239-1247.
- [50] Lang, S and Wullbrandt, D. Rhamnolipids - bio synthesis , microbial production and application potential. *Appl.Microbiol.Biotechnol.*51, 22-32 (1999).
- [51] Matsufuji, M., Nakata, K. and Yoshimoto, A. High production of rhamnolipids by *Pseudomonas aeruginosa* growing on ethanol. *Biotechnol. Prog.* 17, 419-423 (2001).
- [52] Abalos, A., Pinazo, A., Infante, M.R. et al. Physicochemical and antimicrobial properties of new rhamnolipids produced by *Pseudomonas aeruginosa* AT10 from soy bean oil refinery wastes. *Langmuir* 17,1367-1371 (2001).
- [53] Piljac, T and Piljac, G. Use of rhamnolipids in wound healing, treating burn shock, atherosclerosis, organ transplants, depression, schizophrenia and cosmetics (European Patent 1 889 623). Paradigm Biomedical Inc., New York (1999).
- [54] Maier, R.M. and Soberon-Chavez, G. *Pseudomonas aeruginosa* rhamnolipids: biosynthesis and potential applications. *Appl. Microbiol.Biotechnol.* 54, 625-633.
- [55] Fukuoka, T., Morita, T. and Konishi, H. Structural characterization and surface-active properties of a new glycolipid biosurfactant , mono-acylated mannosylerythritol lipid, produced from glucose by *Pseudozyma antarctica*. *Appl. Microbiol.Biotechnol.* 76, 801-810 (2007).
- [56] Masaru, K., Michiko, S. and Shuhei, Y. Skin care cosmetic and skin and agent for preventing skin roughness and skin and agent for preventing skin roughness containing biosurfactants (World Patent 2007/060956). Toyo Boseki Kabu Shiki Kaisha and National Industrial Science and Technology, Osaka, Japan (2007).
- [57] Zang, Y. and R.M. Miller, 1992. Enhanced octadecane dispersion and biodegradation by a *Pseudomonas* rhamnolipid surfactant (Biosurfactant). *applied Environ. Microbiol.*, 58: 3276- 3282.
- [58] Zouboulis, A. I., K.A.Matis, N.K. Lazeridis and P.N. Golyshin , 2003. The use of biosurfactants in flotation: Application for the removal of metal ions. *Mineral Eng.*, 16: 1231- 1236. http://www.aist.go.jp/aist_e/latest_research/2006/20061012/20061012.html.
- [59] Francetti, A., Gandolfi, I., G., Smyth, T.J.P. Banat, I.M. 2010. *Eur. J.Lipid Sci. Technol.*, 112,617.
- [60] Christofi, N, Ivshina, I.B. 2002, *J. Appl. Microbiol.*, 93, 915.
- [61] Haba, E., Pinazo, A., Jauregui, O., Espuny, M. J., Infante, M.R, Manresa, A., 2003, *Biotechl. Bioengineer.*,81, 3.
- [62] Eco-friendly surfactants and moisturizers, Research list, <http://www.kanebo.com/research/skincare/biosurfactants.html>.
- [63] Lin Chen-Ta, Chen Yeh-Chun, Wang Czing- Tzu, Chen Shuen-Yuh, 2011. Characterization of Biosurfactant from a Diesel-oil Degradation Bacterium and Application Potential in Beauty Care Products „2011 3rd International Conference on Chemical, Biological and Environmental Engineering IPCBEE vol.20 (2011) © (2011) IACSIT Press, Singapore.
- [64] Das P, Mukherjee S, Sen R (2008a) Antimicrobial potential of alipoptide biosurfactant derived from a marine Bacillus circulans. *J Appl Microbiol* 104:1675–1684.
- [65] Mireles JR II, Toguchi A, Harshey RM (2001) Salmonella entericaserovar typhimurium swarming mutants with altered biofilmforming abilities: surfactin inhibits biofilm formation. *J Bacteriol*183:5848–5854.
- [66] Merk K, Borelli C, Korting HC (2005) Lactobacilli—bacteria—host interactions with special regard to the urogenital tract. *Int J MedMicrobiol* 295:9–18.
- [67] Rivardo F, Turner RJ, Allegrone G, Ceri H, Martinotti MG (2009)Anti-adhesion activity of two biosurfactants produced by Bacillus spp. prevents biofilm formation of human bacterial pathogens. *Appl Microbiol Biotechnol* 83:541–553.
- [68] Valle J, Da Re S, Henry N, Fontaine T, Balestrino D, Latour-LambertP, Ghigo JM (2006) Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide. *Proc Natl Acad Sci U S A*103:12558–12563.
- [69] Van Hoogmoed CG, Van der Mei HC, Busscher HJ (2004) The influence of biosurfactants released by *S. mitis* BMS on the adhesion of pioneer strains and cariogenic bacteria. *Biofouling*20:261–267.

- [70] Vollenbroich D, Ozel M, Vater J, Kamp RM, Pauli G (1997) Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from *Bacillus subtilis*. *Biologicals* 25:289–297.
- [71] Huang X, Lu Z, Zhao H, Bie X, Lü FX, Yang S (2006) Antiviral activity of antimicrobial lipopeptide from *Bacillus subtilis* fmbj against pseudorabies virus, porcine parvovirus, newcastle disease virus and infectious bursal disease virus in vitro. *Int J Pept Res Ther* 12:373–377.
- [72] Huang X, Lu Z, Bie X, Lü F, Zhao H, Yang S (2007) Optimization of inactivation of endospores of *Bacillus cereus* by antimicrobial lipopeptides from *Bacillus subtilis* fmbj strains using a response surface method. *Appl Microbiol Biotechnol* 74:454–461.
- [73] Remichkova M, Galabova D, Roeva I, Karpenko E, Shulga A, Galabov AS (2008) Anti-herpesvirus activities of *Pseudomonas* sp. S-17 rhamnolipid and its complex with alginate. *Z Naturforsch C* 63:75–81.
- [74] Mimee B, Labbé C, Pelletier R, Bélanger RR (2005) Antifungal activity of flocculosin, a novel glycolipid isolated from *Pseudozyma flocculosa*. *Antimicrob Agents Chemother* 49:1597–1599.
- [75] Teichmann B, Linne U, Hewald S, Marahiel MA, Bölker M (2007) Abiosynthetic gene cluster for a secreted cellobiose lipid with antifungal activity from *Ustilago maydis*. *Mol Microbiol* 66:525–533.
- [76] Kulakovskaya T, Shashkov A, Kulakovskaya E, Golubev W, Zinin A, Tsvetkov Y, Grachev A, Nifantiev N (2009) Extracellular cellobiose lipid from yeast and their analogues: structures and fungicidal activities. *J Oleo Sci* 58:133–140
- [77] Kulakovskaya TV, Golubev WI, Tomashevskaya MA, Kulakovskaya EV, Shashkov AS, Grachev AA, Chizhov AS, Nifantiev NE (2010) Production of antifungal cellobiose lipids by *Trichosporon porosum*. *Mycopathologia* 169:117–123.
- [78] Debode J, De Maeyer K, Perneel M, Pannecoucq J, De Backer G, Höfte M (2007) Biosurfactants are involved in the biological control of *Verticillium microsclerotia* by *Pseudomonas* spp. *J Appl Microbiol* 103:1184–1196.
- [79] Varnier AL, Sanchez L, Vatsa P, Boudesocque L, Garcia-Brugger A, Rabenoelina F, Sorokin A, Renault JH, Kauffmann S, Pugin A, Clement C, Baillieul F, Dorey S (2009) Bacterial rhamnolipids are novel MAMPs conferring resistance to *Botrytis cinerea* in grapevine. *Plant Cell Environ* 32:178–193.
- [80] Tran H, Ficke A, Asiimwe T, Höfte M, Raaijmakers JM (2007) Role of cyclic lipopeptide massetolide A in biological control of *Phytophthora infestans* and in colonization of tomato plants by *Pseudomonas fluorescens*. *New Phytol* 175:731–742.
- [81] Tran H, Kruijt M, Raaijmakers JM (2008) Diversity and activity of biosurfactant-producing *Pseudomonas* in the rhizosphere of black pepper in Vietnam. *J Appl Microbiol* 104:839–851.
- [82] Velmurugan N, Choi MS, Han SS, Lee YS (2009) Evaluation of antagonistic activities of *Bacillus subtilis* and *Bacillus licheniformis* against wood-staining fungi: in vitro and in vivo experiments. *J Microbiol* 47:385–392.
- [83] Snook ME, Mitchell T, Hinton DM, Bacon CW (2009) Isolation and characterization of Leu7-surfactin from the endophytic bacterium *Bacillus mojavensis* RRC 101, a biocontrol agent for *Fusarium verticillioides*. *J Agric Food Chem* 57:4287–4292.
- [84] Mohammadipour M, Mousivand M, Salehi Jouzani G, Abbasalizadeh S (2009) Molecular and biochemical characterization of Iranian surfactin-producing *Bacillus subtilis* isolates and evaluation of their biocontrol potential against *Aspergillus flavus* and *Colletotrichum gloeosporioides*. *Can J Microbiol* 55:395–404.
- [85] Grover M, Nain L, Singh SB, Saxena AK (2010) Molecular and biochemical approaches for characterization of antifungal trait of a potent biocontrol agent *Bacillus subtilis* RP24. *Curr Microbiol* 60:99–106.
- [86] Cao XH, Wang AH, Wang CL, Mao DZ, Lu MF, Cui YQ, Jiao RZ (2010) Surfactin induces apoptosis in human breast cancer MCF-7 cells through a ROS/JNK-mediated mitochondrial/caspase pathway. *Chem Biol Interact* 183:357–362.
- [87] Gudina JE, Rangarajan V, Sen R, Rodrigues RJ (2013) Potential therapeutic application of biosurfactants. *Trends in Pharmacological Sciences*, vol 34: 667–675.
- [88] Morita T, Kitagawa M, Suzuki M, Yamamoto S, Sogabe A, Yanagidani S, Imura T, Fukuoka T, Kitamoto D (2009) A yeast glycolipid biosurfactant, mannosylerythritol lipid, shows potential moisturizing activity toward cultured human skin cells: the recovery effect of MEL-A on the SDS-damaged human skin cells. *J Oleo Sci* 58:639–642.
- [89] Reddy AS, Chen CY, Chen CC, Jean JS, Fan CW, Chen HR, Wang JC, Nimje VR (2009) Synthesis of gold nanoparticles via an environmentally benign route using a biosurfactant. *J Nanosci Nanotechnol* 9:6693–6699.
- [90] Nakanishi M, Inoh Y, Kitamoto D, Furuno T (2009) Nano vectors with a biosurfactant for gene transfection and drug delivery. *J Drug Delivery Sci Technol* 19:165–169.
- [91] Maitani Y, Yano S, Hattori Y, Furuhashi M, Hayashi K (2006) Liposome vector containing biosurfactant-complexed DNA as herpes simplex virus thymidine kinase gene delivery system. *J Liposome Res* 16:359–372.
- [92] Ueno Y, Hirashima N, Inoh Y, Furuno T, Nakanishi M (2007a) Characterization of biosurfactant-containing liposomes and their efficiency for gene transfection. *Biol Pharm Bull* 30:169–172.
- [93] Wang, C. et al. (2013) Surfactin-induced apoptosis through ROS-ERS- Ca²⁺-ERK pathways in HepG2 cells. *Biochem. Biophys.* [http:// dx.doi.org/10. 1007/s12013-013-9676-7](http://dx.doi.org/10.1007/s12013-013-9676-7).
- [94] Isoda, H. et al. (1997) Microbial extracellular glycolipid induction of differentiation and inhibition of protein Kinase C activity of Human promyelocytic leukaemia cell line HL60. *Biosci. Biotechnol. Biochem.* 61, 609–614.
- [95] Chiewpattanakul, P. et al. (2010) Bioproduction and anticancer activity of biosurfactant produced by the dematiaceous fungus *Exophiala dermatitidis* SK80. *J. Microbiol. Biotechnol.* 20, 1664–1671.

- [96] El-Sersy, N.A *et al.*(2012) Antibacterial and anticancer activity of E-poly-L-lysine produced by a marine *Bacillus subtilis* sp.*J. Basic Microbiol.* 52, 513-522.
- [97] Preetha, A. et al. (2005) Surface activity, lipid profiles and their implications in cervical cancer. *J. Cancer Res. Ther.* 1, 180–186.
- [98] Sil J, Das S, Oliveira RG, Amaral PFF, Coelho MAZ. Screening six potential *Yarrowia lipolytica* strains for best lipid, citric acid, biosurfactant and lipase production. Proceedings of 2nd International Conference on Environment, Energy and Biotechnology IPCBEE vol.51 (2013) © (2013) IACSIT Press, Singapore DOI: 10.7763/IPCBEE.2013.V51.22.
- [99] Lang, S., Katsiwela, E., and Wanger, F. Antimicrobial effects of biosurfactants. *Fett. Wiss. Technol. Fat Sci. Technol.* 91, 363-366(1989).
- [100] Vishal Shah,1 Gustavo F. Doncel,Theodoros Seyoum, Kristin M. Eaton,Irina Zalenskaya,2 Rena Hagver, Abul Azim, and Richard Gross. Sophorolipids, Microbial Glycolipids with Anti-Human Immunodeficiency Virus and Sperm-Immobilizing Activities. Antimicrobial agent and Chemotherapy .2005,vol 49, p 4093-4100.
- [101]Konishi, M., T. Morita, T.Fukuoka, T.Imura, K.Kakugawa and D. Kitamoto, 2007. Production of different types of mannosylerythritol lipids as biosurfactants by the newly isolated yeast strains belonging to the genus *Pseudozyma*.*Applied Microbiol. Biotechnol.*, 75:521-531.
- [102]Amaral,P., M.Colao, M.A. Coelho, G.Fontes and M.Nele, 2009.Characterization of a bioemulsifier produced from glycerol and glucose by *Yarrowia lipolytica* .*New Biotechnol.*, 25:s138-s138.
- [103]Huang,X.F., W.Guan, J.Liu, L.J. Lu, Cheng and X.Q. Zhou, 2010. Characterization and polygenetic analysis of bioemulsifier-producing bacteria. *Bioresour.Technol.*,101:317-323.
- [104]Gautam,K.K.and V.k.Tiagi, 2006.Microbial surfactants: Areview. *J. Oleo Sci.*, 55: 155-166.
- [105]Morita, TM., Konishi, T. Fukuka, T. Imura and D. Kitamoto, 2006. Physiological differences in the formation of the glycolipid biosurfactants,Mannosylerythritol lipids, between *Pseudozyma antarctica* and *Pseudozyma aphidis* .*Applied Microbiol.Biotechnol.*, 74: 307-315.
- [106]Sullivan, E.R., 1998. Molecular genetics of biosurfactant production. *Curr. Opin. Biotechnol* .,9: 263-269.
- [107]Kitamoto D, Yanagishita H, ShinboT, Nakane T, Kamisawa C, Nakahara T(1993) Surface active properties and antimicrobial activities of mannosylerythritol lipids as biosurfactants produced by *Candida antarctica* . *J. Biotechnol* 29: 91-96.
- [108]Monteiro, S.A.,G.L. Sasaki, L . M.Souza, J.M. Meira and J. M. Araujo *et al.*, 2007. Molecular and structural characterization of the biosurfactant produced by *Pseudomonas aeruginosa* DAUPE 614. *Chem, Phys. Lipids*, 147: 1-13.